Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|March 28, 2014
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-04-02-2014
- Volume 10
- Issue 4
Covance Expands Global Biologics Capabilities
Author(s)Melanie Sena
Covance adds workspace and scientists to biologics team in Indianapolis facility.
Advertisement
The additional space will be added at its central laboratory facility in Indianapolis, Ind. The expansion, which is planned to open during the second half of 2014, will double the company’s large molecule capacity and is expected to add approximately 100 new positions over the next five years.
In addition to the expansion, the company also appointed Mike Holsapple, PhD, as Covance’s executive director of global immunotoxicology. Holsapple is a member of the Academy of Toxicological Sciences and past president of the Society of Toxicology, with more than 30 years of experience.
Source:
Articles in this issue
over 12 years ago
Pharma Industry Corruption in China Under Scrutinyover 12 years ago
Western CMOs Rise Again, Face New Challengesover 12 years ago
How Will CMO Ownership Changes Impact Market?over 12 years ago
Vetter Implements New Serialization Servicesover 12 years ago
AmerisourceBergen Acquires Minority Interest in Profarmaover 12 years ago
Catalent Increases Investment in Redwood BioscienceAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5